» Articles » PMID: 20237038

P-glycoprotein Function at the Blood-brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-desmethyl-loperamide

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2010 Mar 19
PMID 20237038
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Permeability-glycoprotein (P-gp), an efflux transporter in several organs, acts at the blood-brain barrier to protect the brain from exogenous toxins. P-gp almost completely blocks brain entry of the PET radiotracer (11)C-N-desmethyl-loperamide ((11)C-dLop). We examined the ability of (11)C-dLop to quantify P-gp function in humans after increasing doses of tariquidar, an inhibitor of P-gp.

Methods: Seventeen healthy volunteers had a total of 23 PET scans with (11)C-dLop at baseline and after increasing doses of tariquidar (2, 4, and 6 mg/kg intravenously). A subset of subjects received PET with (15)O-H(2)O to measure cerebral blood flow. Brain uptake of (11)C-dLop was quantified in 2 ways. Without blood data, uptake was measured as area under the time-activity curve in the brain from 10 to 30 min (AUC(10-30)). With arterial blood data, brain uptake was quantified with compartmental modeling to estimate the rates of entry into (K(1)) and efflux from (k(2)) the brain.

Results: Brain uptake of radioactivity was negligible at baseline and increased only slightly (approximately 30%) after 2 mg of tariquidar per kilogram. In contrast, 4 and 6 mg of tariquidar per kilogram increased brain uptake 2- and 4-fold, respectively. Greater brain uptake reflected greater brain entry (K(1)), because efflux (k(2)) and cerebral blood flow did not differ between tariquidar-treated and untreated subjects. In the subjects who received the highest dose of tariquidar (and had the highest brain uptake), regional values of K(1) correlated linearly with absolute cerebral blood flow, consistent with high single-pass extraction of (11)C-dLop. AUC(10-30) correlated linearly with K(1).

Conclusion: P-gp function at the blood-brain barrier in humans can be quantified using PET and (11)C-dLop. A simple measure of brain uptake (AUC(10-30)) may be used as a surrogate of the fully quantified rate constant for brain entry (K(1)) and thereby avoid arterial sampling. However, to dissect the function of P-gp itself, both brain uptake and the influx rate constant must be corrected for radiotracer delivery (blood flow).

Citing Articles

Hypoxia tolerance determine differential gelsenicine-induced neurotoxicity between pig and mouse.

Huang C, Zuo M, Qi X, Gong M, Xu W, Meng S BMC Med. 2025; 23(1):156.

PMID: 40075370 PMC: 11905507. DOI: 10.1186/s12916-025-03984-5.


Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?.

Gulave B, Lesmana A, de Lange E, van Hasselt J J Pharmacokinet Pharmacodyn. 2025; 52(1):11.

PMID: 39776000 PMC: 11706904. DOI: 10.1007/s10928-024-09957-0.


[C]Metoclopramide PET can detect a seizure-induced up-regulation of cerebral P-glycoprotein in epilepsy patients.

Biali M, Breuil L, Jackwerth M, Mairinger S, Weber M, Wolfl-Duchek M Fluids Barriers CNS. 2024; 21(1):87.

PMID: 39465417 PMC: 11514750. DOI: 10.1186/s12987-024-00588-8.


ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.

Lentzas A, de Gooijer M, Zuidema S, Meurs A, Citirikkaya C, Venekamp N Fluids Barriers CNS. 2024; 21(1):62.

PMID: 39103921 PMC: 11301932. DOI: 10.1186/s12987-024-00562-4.


St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.

Biali M, Wolfl-Duchek M, Jackwerth M, Mairinger S, Weber M, Bamminger K Clin Transl Sci. 2024; 17(5):e13804.

PMID: 38700454 PMC: 11067874. DOI: 10.1111/cts.13804.


References
1.
Liow J, Kreisl W, Zoghbi S, Lazarova N, Seneca N, Gladding R . P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med. 2008; 50(1):108-15. PMC: 2652692. DOI: 10.2967/jnumed.108.056226. View

2.
Luna-Tortos C, Fedrowitz M, Loscher W . Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008; 55(8):1364-75. DOI: 10.1016/j.neuropharm.2008.08.032. View

3.
Seneca N, Zoghbi S, Liow J, Kreisl W, Herscovitch P, Jenko K . Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med. 2009; 50(5):807-13. PMC: 2792991. DOI: 10.2967/jnumed.108.058453. View

4.
Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S . A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res. 2009; 15(10):3574-82. PMC: 7213754. DOI: 10.1158/1078-0432.CCR-08-0938. View

5.
Kannan P, John C, Zoghbi S, Halldin C, Gottesman M, Innis R . Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009; 86(4):368-77. PMC: 2746858. DOI: 10.1038/clpt.2009.138. View